Background. Genetic lipoprotein disorders have been associated with premature coronary artery disease (CAD).
cholesterolemia (FH),2 familial combined hyperlipidemia (FCH),3-5 and familial hypoalphalipoproteinemia (FHA),6 have been associated with an increased risk of premature CAD. The role of plasma lipids and lipoproteins in the development of CAD has been shown in large prospective7-8 and case-control studies.9-10 The protein content of low density lipoproteins (LDL) and the main apolipoproteins of high density lipoproteins (HDL), i.e., apolipoprotein (apo) B and apo A-I,1-14 as well as lipoprotein (a) [Lp(a)] and apo (a)15"6 have been shown in some studies, but not all, to be better markers for the presence of CAD than elevated LDL cholesterol or decreased HDL cholesterol levels. Elevation of LDL apo B with normal (or near-normal) lipid values (hyperapobetalipoproteinemia) is associated with premature CAD and has been shown to segregate in family members." Lp(a) excess also is associated with premature CAD and is present in families of affected individuals. The modes of inheritance for many of these disorders is thought to be autosomal dominant or polygenic, with varying degrees of penetrance and/or expression in adulthood. With the exception of FH,2 familial defective apo B-100,17 familial dysbetalipoproteinemia (type III hyperlipoproteinemia),18 and rare disorders of the apo AI-CIII-AIV gene cluster,'9'20 the molecular defects of most familial lipoprotein disorders associated with premature CAD are unknown. In FH, multiple disorders of the LDL receptor gene have been identified, and the disease is transmitted in a Mendelian dominant fashion. 21, 22 The prevalence of lipid disorders is increased in patients with premature CAD. However, the type and prevalence of familial dyslipidemias have not been well characterized since the description of FCH in CAD patients,3-5 which was based on measurements of total cholesterol and triglyceride concentrations and the lipoprotein electrophoresis pattern.
The purpose of the present study was to determine the type and prevalence of dyslipidemias in patients with premature coronary disease. The genetic contribution of lipoprotein and apolipoprotein levels was assessed by comparing parental with offspring plasma levels of various lipid parameters.
Methods Patients
From July 1986 through December 1987, 259 consecutive patients referred to our hospital for coronary angiography were included in the study if they were Caucasian and less than 60 years of age at the time of angiography and had significant CAD, defined as >50% stenosis of one or more epicardial coronary artery. Patients with <50% stenosis were excluded (n=25), as were patients older than 60 years and those receiving lipid-lowering medications (n = 1). All angiograms were reviewed by three cardiologists, including one of the authors (J.J.G.). The other two cardiologists were blinded to the study and scored the angiograms for diagnostic purposes. The majority of the patients selected (97%) had severe twoor three-vessel disease. There were 214 men (83%) and 45 women (17%) in the group. The referral base of the New England Medical Center Hospital includes the greater Boston area and eastern Massachusetts. Information on use of lipidlowering drugs, f3-adrenergic blocking agents, and diuretics and history of hypertension, diabetes mellitus, and cigarette smoking was obtained.
All patients were seen in the hospital by one of the authors (J.J.G.). Information on the presence of coronary disease was gathered on first-degree relatives, parents, and grandparents by history. The country of origin of relatives also was determined. We attempted to study all kindreds consisting of patients who had a minimum of two offspring and a genetically unrelated spouse available for blood sampling. A letter confirming the appointment for family studies was sent, and telephone confirmation was made to ensure compliance. Of 259 patients with premature CAD, 36 were unmarried or had insufficient children for this study. Of the remaining 223 families, 50 (22%) did not wish to take part in the study; 44 (20%) volunteered but were unable to participate; 21 (9%) were lost to follow-up; and 108 families (49%) were sampled. In six families, not enough first-degree relatives were available for analysis, and these kindreds were excluded from the phenotype analysis. There were 87 men (85.3%) and 15 women relatives (3.75 per proband, including 16 parents), 23 second-degree relatives, and 96 genetically unrelated spouses; 88.6% of offspring identified were sampled. A total of 603 subjects were studied. None of the women probands were on hormonal therapy at the time of sampling. Data on the use of hormones were not obtained in first-degree relatives of the probands. Informed consent was obtained from all participating family members by using a protocol approved by the Human Investigation Review Committee of the New England Medical Center Hospital and Tufts University School of Medicine. Parental consent was obtained for those under 18 years of age.
Controls
To classify values of probands and first-degree relatives, we used the Lipid Research Clinics (LRC) data base's 90th percentile age-and sex-specific values for total cholesterol, triglycerides, and LDL cholesterol and the 10th percentile values for HDL cholesterol as cutoff points. 23 No age or sex norms for apo A-I, apo B, and Lp(a) are available from the LRC study; apo A-I and apo B were therefore measured on a sample of 3,541 participants in cycle 3 of the Framingham Offspring Study. Age and sex distribution were used for the cutoff points (<10th percentile for apo A-I and >90th percentile for apo B) in the present study. Lp(a) was determined on 1,240 men and 1,309 women, free of cardiovascular disease, from the Framingham Offspring cohort. The 90th percentile was determined to be 39 mg/dl in men and 39.5 mg/dl in women at a mean age of 50 years. As comparison groups for the probands, we used 901 healthy men aged 40-60 years (mean+SD age, 49+6 years) and 1,125 healthy women aged 40-60 years (mean±SD age, 49±6 years) from the Framingham Offspring Study who had no evidence of cardiovascular disease. Triglycerides and Lp(a) were log10-transformed to approximate the normal distribution.
Lipid, Lipoprotein, and Apolipoprotein Measurements
All patients and relatives were sampled in the freeliving state at least 1 month after their diagnostic catheterization and at least 6 weeks after major surgery or myocardial infarction. The sampling took place in the Metabolic Research Unit of the U.S. Department of Agriculture Human Nutrition Research Center on Aging at Tufts University. Subjects were sampled after a 12-14-hour overnight fast (morning medication, including insulin, was allowed); subjects were asked to refrain from alcohol consumption for 24 hours before the sampling. Blood sampling was carried out after subjects had been in the sitting position for at least 10 minutes and after blood pressure measurements were performed. Thirty milliliters of blood was drawn from an antecubital vein in EDTA-containing tubes to a final concentration of 1.2 mg/ml and put on ice. Plasma was isolated by centrifugation (2,500 rpm for 20 minutes at 4°C), and multiple aliquots were stored immediately at -80°C for later apo A-I, apo B, and Lp(a) determinations. Blood cells were resuspended in 0.9% NaCI for subsequent DNA isolation.
Plasma total cholesterol and triglyceride concentrations were determined enzymatically. HDL cholesterol (14.7%) identified as probands, with 382 first-degree also was measured enzymatically after dextran-Mg` precipitation.24'25 Our laboratory meets the performance criteria of the Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization program. In most subjects, LDL cholesterol was estimated with the Friedewald formula.24-26 However, in cases where the plasma triglyceride levels were >400 mg/dl, cholesterol was measured in the density > 1.006 g/ml infranate plasma after ultracentrifugation; LDL cholesterol was then calculated by subtracting HDL cholesterol from infranate cholesterol.23 Apo A-I and apo B were determined by noncompetitive ELI-SAs.2728 These assays were standardized using amino acid analysis of purified protein standards. Lp(a) was measured using a commercially available ELISA (Terumo Medical Corp., Elkton, Md.), which uses two antisera, one monoclonal antibody that does not crossreact with plasminogen, and a polyclonal antibody that is specific for the apo (a) protein of Lp(a). The assay is standardized with respect to the total Lp(a) particle. Results are expressed in milligrams per deciliter of Lp(a). Coefficients of variance for this assay were 2.46% for intrarun and 3.33% for interrun variations, respectively, and <10% for other apolipoprotein assays.
Lipoprotein Abnormalities
To classify lipid disorders, we defined hypertriglyceridemia as a plasma triglyceride level >90th percentile value of ageand sex-matched control subjects. Similarly, hypercholesterolemia was defined as a plasma level of LDL cholesterol >90th percentile, and hypoalphalipoproteinemia was defined as a plasma level of HDL cholesterol <10th percentile, based on the LRC population study. 23 The LRC data for lipid and lipoprotein levels were used rather than the Framingham Study data base because the former includes data on children. However, cutoff-point values for either sample were very similar. We have avoided defining hyperlipoproteinemias by types IV29; rather, we have used the terms as defined above.
The criteria used to define a familial dyslipidemia are as follows: Abnormalities found in probands alone and not in any first-degree relatives were called "sporadic" and the family was considered "normal." In cases where the spouse was affected and the proband was not and segregation was found in the children, the family was labeled "normal" for the purposes of this study. If the proband was affected with a lipoprotein or apolipoprotein abnormality and at least one first-degree relative had a lipoprotein or apolipoprotein abnormality, the kindred was considered to have a familial lipoprotein abnormality. FH was defined as elevated LDL cholesterol only, regardless of the presence of xanthomas or xanthelasmas and the finding of this same abnormality in one or more first-degree relatives. Familial hypertriglyceridemia was defined as an elevated triglyceride level and the presence of the same abnormality in at least one first-degree relative. FHA was defined as low HDL cholesterol only and the presence of the same abnormality in at least one first-degree relative. Familial Lp(a) excess was defined as an elevated Lp(a) level (>39 mg/dl for men, >39.5 mg/dl for women) in the proband and at least one first-degree relative. Familial hyperapo B was defined as apo B >90th percentile in normal lipid and lipoprotein levels. Familial apo A-I deficiency was defined as apo A-I levels < 10th percentile with normal lipid values, including HDL cholesterol. FCH was defined as the finding of an elevated triglyceride level and/or an elevated LDL cholesterol level (>90th percentile) in the proband and at least one first-degree relative, with the stipulation that both abnormalities had to be present in the kindred. Familial hypertriglyceridemia with hypoalphalipoproteinemia was defined as an elevated triglyceride level and/or a low HDL cholesterol level (< 10th percentile) in the proband and at least one first-degree relative, with the stipulation that both abnormalities had to be present within the kindred. We call this entity familial dyslipidemia.
Statistical Analysis
Data were stored on a VAX 11/780 (Digital Equipment Corp., Maynard, Mass.) on the data base RS/1 (BBN Software, Cambridge, Mass.). The RPL language was used for all programming (BBN software); Z scores were determined by using a built-in subroutine. To calculate correlation coefficients between parents and offspring for biochemical variables, the Z score was determined for each lipoprotein and apolipoprotein variable to correct for age and sex differences. Pearson's multiple regression analysis, using the SAS statistical package (SAS Institute, Cary, N.C.) was used to determine correlation coefficients between lipoprotein and apolipoprotein levels in proband-spouse, midparentmidoffspring, and proband (or spouse)-offspring combinations. Because we did not observe age and sex differences for Lp(a) levels in this study, we used uncorrected Lp(a) data for these correlation analyses. Differences in lipids, lipoproteins, and apolipoproteins were analyzed by t tests, and differences in the frequency of lipid disorders were assessed by x2 analysis. Covariate analysis between cases and controls was performed using a general linear model (GLM) procedure. The data were adjusted for body mass index, sex, age, use of ,8-blockers, cigarette smoking, and hypertension.
Results
The mean age of the probands was 51±6 years (age range, 34-59 years). When the CAD cases were compared with Framingham controls, prevalence rates for smoking (within the past 2 years; 44% versus 28%, p<0.01), diabetes (11% versus 3%, p<0.001), and hypertension (45% versus 20%, p<0.01) were significantly higher in the CAD group than in the control group. Mean age in men with CAD was 51±6 years compared with 49±6 years in the male controls (p<0.05), and mean age in women with CAD was 51+3 years compared with 49±6 years in the female controls (p=NS).
Lipid, lipoprotein, and apolipoprotein levels in men and women with CAD are shown in Table 1 and are compared with levels of male and female controls from the Framingham Offspring Study, cycle 3. (3-Adrenergic antagonists (P-blockers) can alter lipid and lipoprotein cholesterol levels, so we determined the effects of p-blocker use on 236 patients from which the probands were selected in whom }3-blocker data were available. For such comparisons, we assumed that patients receiving ,-blockers did not differ significantly from those not the proband and at least one first-degree relative, with receiving such medication. There were 94 patients not mg/dl, p=0.718) did not differ significantly between patients not receiving and those receiving ,-blockers. Analysis by ,B-blocker (propranolol, metoprolol, atenolol, and others) or sex did not affect the results (data not shown).
The results of a covariate analysis are presented in Table 2 . The data on lipids, lipoproteins, and apolipoproteins were adjusted for sex, age, body mass index, smoking status, use of ,-blockers, and hypertension. This analysis revealed that triglycerides, LDL cholesterol, and apo B were no longer higher in the CAD probands after adjusting for covariates.
With the criteria outlined in "Methods," the prevalence of lipoprotein and apolipoprotein abnormalities was determined in probands alone (Table 3 ) and within the familial context (Table 4) . A lipoprotein or apolipoprotein abnormality was identified in 75 probands (73.5%). In 20 of these patients (19.6% of all CAD index cases), no clear familial segregation was identified, and the proband was classified as having a sporadic Values are given as mean±SEM.
lipid disorder (see "Methods"). Therefore, 53.9% of the CAD probands were documented as having a familial lipoprotein or apolipoprotein disorder as previously defined.
In the probands, the prevalence of lipoprotein and apolipoprotein abnormalities were hypoalphalipoproteinemia, 39.2%; elevated apo B, 30.4%; reduced apo A-I, 28.4%; elevated triglyceride levels, 22.5%; Lp(a) excess, 18.6%; and hypercholesterolemia, 10 .8% (these groups were not mutually exclusive). Our assay for apo B measures total plasma apo B. When family members were considered, the prevalence of familial lipoprotein abnormalities did not always follow the proband's phenotype (Table 4 ). Isolated lipid disorders were infrequent; combined lipoprotein disorders were frequent. The majority of probands with low HDL cholesterol also had first-degree relatives with elevated triglycerides; similarly, many probands with a lipoprotein abnormality were part of families with combined disorders. The most common familial dyslipidemias were Lp(a) excess, seen in 19 families (18.6%), including 13 (12.7%) with no other lipid abnormalities ( Figure 1A ); hypertriglyceridemia with low HDL cholesterol, 15 families (14.7%) ( Figure 1B) ; FCH (elevated triglycerides and/or LDL cholesterol), 14 families (13.7%) with (11.7%) or without (2%) low HDL cholesterol ( Figure  1C) ; and FHA, four families (4%) ( Figure 1D ). FH was seen in three families, two of whom had classic FH with tOf the kindreds, 6.9% had two abnormalities; however, each case was counted only once, and the overlaps are indicated.
tBoth proband and spouse were dyslipidemic and children were affected; therefore, the type of lipid disorder could not unequivocally be assigned to the proband. tendinous xanthomas. On Southern blot analysis, a 10-kilobase (kb) deletion of the 5' end of the LDL receptor was detected in one of the patients (French-Canadian mutation, H. Hobbs, Dallas, Tex., personal communication).2' This patient also had familial hypertriglyceridemia combined with FHA. Another family had hypercholesterolemia without tendinous xanthomas. One family had isolated familial hypertriglyceridemia (1%). Levels of apo A-I and apo B further refined the analysis; five kindreds (4.9%) had elevated apo B as the sole abnormality, and one kindred (1%) had decreased apo A-I only. An additional three (3%) had an unclassifiable lipoprotein disorder. When Lp(a), apo B, and apo A-I were included in the analysis, 55 kindreds (53.9%) manifested a familial lipoprotein disorder, and 6.9% of all kindreds had more than one disorder (Table 4 ).
There were 20 patients (19.6%) with dyslipidemia in whom no familial segregation was observed; these cases were defined as "sporadic" dyslipidemias. In 24 patients (23.5%), no lipid disorder was identified. Thus, of 44 probands with no familial lipoprotein disorder, 20 (43%) had a sporadic dyslipidemia. Ten of these index cases were diabetic. In two, a pattern consistent with FCH was found; in two other subjects, Lp(a) excess was identified; in two additional subjects, a sporadic hyperlipoproteinemia was found (both with low HDL cholesterol); and in the remaining four subjects, no lipoprotein abnormality was identified.
The lipoprotein and apolipoprotein levels in male probands with the most common disorders are shown in Table 5 (there were too few women in each category for meaningful comparison). It is noteworthy that patients with FHA as well as those with familial hypertriglyceridemia with hypoalphalipoproteinemia and familial Lp(a) excess had mean total cholesterol levels below 200 mg/dl. Familial Lp(a) excess without other lipoprotein abnormalities occurred in 13 kindreds. In those families, lipoprotein cholesterol levels were not significantly different from those of the control group.
The genetic relations of the various lipid and apolipoprotein parameters were assessed by calculating correlation coefficients for lipid, lipoprotein cholesterol, and apolipoprotein levels in proband-offspring, midparent- midoffspring, and spouse-offspring combinations and comparing them with proband-spouse pairs. An index of environmental influence, such as shared household or diet, on lipid parameters can be gleaned from probandspouse correlations. There was a significantly positive correlation for HDL cholesterol (r=0.127, p<O.05) and apo B (r=0.138, p<0.05) and an inverse correlation for LDL cholesterol (r=-0.158, p<O.O1) in probandspouse comparisons. The correlation in triglyceride concentrations between probands and spouses did not reach statistical significance (r=0.111, p>O.05). There was a significant correlation for total cholesterol (r=0.271, p<O.OO1), triglycerides (r=0.160, p<0.O1), very low density lipoprotein (VLDL) cholesterol (r=0.134, p<0.05), LDL cholesterol (r=0.289, p<O.OOl), HDL cholesterol (r=0.284, p<O.OO1), apo B (r=0.252, p<O.OO1), apo A-I (r=0.276, p<O.OO1), and Lp(a) (r=0.614, p<O.OO1) between parents and offspring. The correlation coefficients were somewhat less for proband-offspring or spouse-offspring but were still significant for cholesterol, LDL cholesterol, HDL cholesterol, apo B, apo A-I, and Lp(a) ( Table 6 ). There were no significant differences in Lp(a) levels between men and women in the control groups, nor were there significant correlations between age and Lp(a) levels in the control groups (men and women) or in the group of patients with CAD, their spouses, and their relatives.
Discussion
The characterization of most familial lipid disorders has been fraught with difficulties; in FCH, the phenotypic expression of the disease may vary between siblings and the proband; FHA has been described frequently, but in many families, elevated triglycerides were present.30 31 The expression of these lipid disorders may not be evident until adulthood. The lack of specificity in biochemical or molecular markers for each disorder has added to the difficulty in differentiating patients with various lipoprotein disorders. Plasma apo B or VLDL apo B may be a marker for FCH, whereas elevated LDL apo B may be a marker for a normolipidemic subset of FCH, i.e., familial hyperapobetali-poproteinemia232 Single-gene disorders leading to extreme levels of lipoproteins are rare and do not account for much of the variability in plasma lipoprotein levels within a population. These disorders account for a small fraction of lipid disorders within a group of patients with CAD.33 Single-gene effects that lead to moderate variation in lipoprotein parameters remain an important area of investigation.
In the present study, the most common disorders are those in which there is combined elevation of apo B-containing particles (VLDL, LDL, or both), often with decreased HDL cholesterol. Because of the interrelation among the various lipoproteins, classification of each disorder within a specific lipoprotein class (i.e., VLDL, LDL, or HDL) or by hyperlipoproteinemia type is impractical. The common lipoprotein disorders will be discussed separately.
Familial Hypertriglyceridemia With Hypoalphalipoproteinemia (Familial Dyslipidemia)
There are several lines of evidence suggesting that familial hypertriglyceridemia with hypoalphalipoproteinemia (FTgH) is a distinct entity. The inverse relation between triglycerides and HDL cholesterol has long been known. 34 The prevalence of hypertriglyceridemia with hypoalphalipoproteinemia in the general population is higher than expected if the two variables were independent. In previous studies of FHA, several families also had hypertriglyceridemia.3031 In the present study, FTgH was one of the most common familial lipid abnormalities in patients with premature CAD, being present in 14.7% of the probands (Table 4 ). It is of interest that the prevalence of FTg without hypoalphalipoproteinemia was 1% in CAD families; the prev- alence of hypertriglyceridemia without low HDL cholesterol did not differ significantly between CAD patients and control subjects. This suggests that elevated triglyceride levels are important as a risk factor only when associated with another lipoprotein abnormality (elevated LDL cholesterol or decreased HDL cholesterol). The etiology of FTgH is unknown. As in FCH, apo B levels were increased and HDL cholesterol levels were decreased ( Table 5 ). Whether FTgH and FCH share a common metabolic etiology is uncertain; in FTg, hyperproduction of triglycerides has been documented, whereas in FCH (or in familial hyperapobetalipoproteinemia), there is overproduction of apo B.34-36
The importance of this disorder is its association with a normal total cholesterol. We suggest that this entity be called familial dyslipidemia to distinguish it from FCH. FCH FCH, as defined by elevated triglycerides, LDL cholesterol, or both, was one of the most common dyslipidemias found in the present study. This disorder was seen in 13.7% of probands (2% with normal HDL cholesterol and 11.7% with decreased HDL cholesterol levels). In affected family members, increased hepatic apo B production rates have been reported. 37 The apo B levels were elevated (Table 5 ). A closely related disorder, hyperapobetalipoproteinemia (elevated apo B levels in the presence of normal lipid levels), is probably a variant of FCH. In this study, five families (5%) had elevated apo B without abnormal lipoprotein cholesterol levels. We did not, however, determine the prevalence of hyperapobetalipoproteinemia as described by Sniderman et a32 because our assay for apo B measures total plasma apo B but not LDL apo B."
FHA
Once thought to be a common lipid disorder, FHA is most often associated with hypertriglyceridemia, including FCH. Patients with rare disorders of the apo A-I-C-III-A-IV gene cluster and those with Tangier disease and other unusual disorders of HDL metabolism38 exhibit severely depressed HDL cholesterol levels. These cases are extremely rare. In this study, 4% of the families had hypoalphalipoproteinemia, and 1% had a decreased apo A-I as the sole abnormality.
FH
FH may be due to a variety of mechanisms. Although LDL receptor defects underlie many severe hypercholesterolemic subjects, defective apo B-100 and disorders of hepatic overproduction of LDL particles may account for a substantial number of cases.39 The prevalence of hypercholesterolemia was lower than that found by Goldstein et al. 3 In one of our cases, hypertriglyceridemia with hypoalphalipoproteinemia also was present.
The prevalence of LDL receptor defects in this cohort with CAD appears to be on the order of 3%. Other mechanisms may play a role in FH, such as defects within the apo B gene, which decrease binding to the LDL receptor'7 or overproduction of LDL particles.
Familial Lp(a) Excess
Familial Lp(a) excess was seen in 18.6% of our families. Elevated levels of Lp(a) appear to be inversely correlated with the molecular weight of apo (a) and the number of kringlelike domains in the protein. 40 The pathogenic mechanisms by which Lp(a) enhances atherosclerosis may be related to its cholesterol ester content or the antithrombolytic effects of the particle. 40 Lp(a) appears to be a highly heritable trait. Parentoffspring correlations indicate that this may be the lipoprotein disorder that has the strongest genetic determinant.
The molecular basis for most of these disorders is unknown. One approach in finding a genetic basis has been the candidate gene approach, in which the genes for the apolipoproteins found in abnormal amounts in these disorders were investigated for genetic polymorphisms.4' Thus, genetic variability within the apo Band apo A-I-C-III-A-IV genes has been investigated by restriction fragment-length polymorphisms (RFLP) analysis in patients with a variety of lipid disorders or vascular problems. Some RFLPs have been associated with altered lipid values in some but not all studies; these associations have, for the most part, not been consistent in various populations. In the present study, no RFLP of the apo B gene42 or the apo A-I-C-III-A-IV gene complex43 appeared to segregate with the lipoprotein disorders outlined above. A few rare disorders, including hypobetalipoproteinemia, familial defective apo B-100,17 and defects of the apo A-I-C-III-A-IV gene complex,'1920 have been documented in the apolipoprotein genes; these have a profound effect on plasma lipid levels but do not contribute to any significant extent to plasma lipoprotein levels within a population because of their low frequency. 44 The cutoff points used in the present study, in which we assumed that the 90th or 10th percentile of a variable constituted an abnormal level, may have led to an overestimation of familial lipoprotein disorders. There was no control for environmental influences within individual families. The effect of diet was not controlled for, nor were other environmental variables such as exercise, body mass index, and cigarette smoking. Because most of our patients were referred from community hospitals, the sampling may be biased toward patients with more severe CAD. Therefore, these results may not be representative of the population at large. However, plasma lipoprotein cholesterol, apo A-I and apo B, and Lp(a) were not significantly different in these probands than in 321 men with premature CAD on whom we reported previously.45 46Sampling patients with cardiovascular events during the acute episode may lead to misclassification of lipid disorders. Waiting 6 weeks after acute myocardial infarction is necessary to best approximate lipoprotein cholesterol levels present before the event (reviewed in Reference 47).
The phenotypic assignment of individual families may not precisely reflect accurate genotypes. Furthermore, it is likely that the disorders discussed above have a polygenic etiology, in which case the chance association of several genetic variations will have an effect on plasma lipoprotein levels. This may explain in part the patterns of inheritance of these disorders in which an affected offspring may have inherited only one anomaly and thus may reveal a different lipid disorder than the proband. Phenotypic expression has been explained by incomplete penetrance, expression of the disorder in adults but not in children, or coexisting environmental variables such as diet, exercise, hormonal status, or ponderosity. One also must consider the inheritance of several unlinked genetic disorders, each with an effect on plasma lipoprotein levels. Despite these caveats, familial dyslipidemias were identified in more than half of the probands with premature CAD. Most of these disorders were associated with normal total cholesterol or LDL cholesterol levels.
No single lipoprotein parameter will identify all patients at risk for CAD. From the data presented here, it appears that triglyceride, HDL cholesterol, apo B, and Lp(a) levels are useful markers for the detection of familial lipid disorders. LDL cholesterol elevation, although strongly associated with the development of CAD, is an infrequent finding in CAD probands. The high prevalence of lipid disorders in offspring and first-degree relatives makes it mandatory to sample children of dyslipidemic probands with premature CAD.
